Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Safety/Tolerability of HF0220 and Its Effect on Biochemical Markers Relevant to Patients With a Diagnosis of Mild to Moderate Alzheimer' Disease

NCT00357357 is registered in ClinicalTrials.gov with Hunter-Fleming Ltd as lead sponsor.

NCT NCT00357357
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00357357 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Safety/Tolerability of HF0220 and Its Effect on Biochemical Markers Relevant to Patients With a Diagnosis of Mild to Moderate Alzheimer' Disease
Lead sponsor
Hunter-Fleming Ltd
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2006
Completion date
August 31, 2008
Enrollment
40 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease